Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 1,146 INR
Change Today +7.80 / 0.69%
Volume 528.6K
As of 7:06 AM 03/30/15 All times are local (Market data is delayed by at least 15 minutes).

torrent pharmaceuticals ltd (TRP) Snapshot

Open
1,132
Previous Close
1,138
Day High
1,158
Day Low
1,131
52 Week High
01/28/15 - 1,232
52 Week Low
04/1/14 - 520.25
Market Cap
193.9B
Average Volume 10 Days
147.2K
EPS TTM
39.23
Shares Outstanding
169.2M
EX-Date
02/2/15
P/E TM
29.2x
Dividend
10.00
Dividend Yield
0.87%
Current Stock Chart for TORRENT PHARMACEUTICALS LTD (TRP)

Related News

No related news articles were found.

torrent pharmaceuticals ltd (TRP) Related Businessweek News

No Related Businessweek News Found

torrent pharmaceuticals ltd (TRP) Details

Torrent Pharmaceuticals Limited, together with its subsidiaries, manufactures and sells branded and unbranded generic pharmaceutical products in India and internationally. The company offers its products in therapeutic areas of cardiovascular, central nervous system, gastrointestinal, anti-infective, diabetology, and pain management areas. It offers products in the form of tablets, capsules, and parenterals. The company’s active pharmaceutical ingredients comprise nicorandil, risperidone, venlafaxine hydrochloride, ropinarole hydrochloride, duloxetine hydrochloride, ormeloxifen hydrochloride, nebivolol hydrochloride, lamotrigine, sertraline hydrochloride, and clopidogrel bisulphate, as well as atomoxatine hydrochloride, rivastigmine hydrogen tartrate, and esomeprazole sodium. It also provides contract manufacturing services primarily for human insulin. The company was formerly known as Trinity Laboratories and changed its name to Torrent Pharmaceuticals Limited in 1971. Torrent Pharmaceuticals Limited was founded in 1959 and is based in Ahmedabad, India. Torrent Pharmaceuticals Limited is a subsidiary of Torrent Private Limited.

9,540 Employees
Last Reported Date: 07/2/14
Founded in 1959

torrent pharmaceuticals ltd (TRP) Top Compensated Officers

Executive Vice Chairman, Managing Director, M...
Total Annual Compensation: 313.0K
Director of Research & Development, Whole-Tim...
Total Annual Compensation: 27.4M
Compensation as of Fiscal Year 2014.

torrent pharmaceuticals ltd (TRP) Key Developments

Torrent Pharmaceuticals Ltd Recommends Interim Dividend, Payable on February 10, 2015

Torrent Pharmaceuticals Ltd. has informed that the Board of Directors of the company at its meeting held on January 28, 2015, has declared an interim dividend of INR 5.00 per equity share of INR 5 each fully paid up. The dividend amount will be paid /dispatched on February 10, 2015.

Torrent Pharmaceuticals Ltd. Announces Audited Standalone Earnings Results and Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended December 31, 2014

Torrent Pharmaceuticals Ltd. announced audited standalone earnings results and unaudited consolidated earnings results for the third quarter and nine months ended December 31, 2014. For the quarter, on standalone basis, the company's net sales (net of excise duty) were INR 7,960 million compared with INR 7,090 million a year ago. Net income from operations was INR 8,060 million compared with INR 7,330 million a year ago. Profit from operations before other income finance costs was INR 1,000 million compared with INR 1,520 million a year ago. Profit from ordinary activities before tax was INR 1,220 million compared with INR 1,460 million a year ago. Net profit was INR 1,030 million or INR 6.05 per basic and diluted share compared with INR 1,140 million or INR 6.74 per basic and diluted share a year ago. For the nine months, on standalone basis, the company's net sales (net of excise duty) were INR 25,320 million compared with INR 22,840 million a year ago. Net income from operations was INR 25,790 million compared with INR 24,110 million a year ago. Profit from operations before other income finance costs was INR 5,730 million compared with INR 6,620 million a year ago. Profit from ordinary activities before tax was INR 6,510 million compared with INR 6,500 million a year ago. Net profit was INR 5,200 million or INR 30.71 per basic and diluted share compared with INR 5,100 million or INR 30.16 per basic and diluted share a year ago. For the quarter, on consolidated basis, the company's net sales (net of excise duty) were INR 11,560 million compared with INR 9,900 million a year ago. Net income from operations was INR 11,680 million compared with INR 10,150 million a year ago. Profit from operations before other income finance costs was INR 1,860 million compared with INR 1,940 million a year ago. Profit from ordinary activities before tax was INR 2,010 million compared with INR 1,880 million a year ago. Net profit was INR 1,670 million or INR 9.86 per basic and diluted share compared with INR 1,580 million or INR 9.34 per basic and diluted share a year ago. EBITDA was INR 3,050 million against INR 2,250 million a year ago. For the nine months, on consolidated basis, the company's net sales (net of excise duty) were INR 34,510 million compared with INR 28,290 million a year ago. Net income from operations was INR 34,990 million compared with INR 29,590 million a year ago. Profit from operations before other income finance costs was INR 7,270 million compared with INR 5,380 million a year ago. Profit from ordinary activities before tax was INR 7,850 million compared with INR 5,270 million a year ago. Net profit was INR 6,210 million or INR 36.67 per basic and diluted share compared with INR 4,200 million or INR 24.79 per basic and diluted share a year ago. EBITDA was INR 10,440 million against INR 6,300 million a year ago.

Torrent Pharmaceuticals Ltd., Q3 2015 Earnings Call, Jan 29, 2015

Torrent Pharmaceuticals Ltd., Q3 2015 Earnings Call, Jan 29, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TRP:IN 1,146.05 INR +7.80

TRP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Divi's Laboratories Ltd 1,810 INR +15.80
Ipca Laboratories Ltd 649.75 INR +5.10
Jubilant Life Sciences Ltd 153.85 INR +4.35
Piramal Enterprises Ltd 866.25 INR +7.30
Wockhardt Ltd 1,862 INR +27.30
View Industry Companies
 

Industry Analysis

TRP

Industry Average

Valuation TRP Industry Range
Price/Earnings 22.7x
Price/Sales 4.2x
Price/Book 8.3x
Price/Cash Flow 19.3x
TEV/Sales 3.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TORRENT PHARMACEUTICALS LTD, please visit www.torrentpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.